Metabolic dysfunction-associated steatohepatitis+1
Not recruitingStudy of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression
Study of resmetirom (MGL-3196) in patients with Non-Alcoholic Steatohepatitis (NASH) to prevent liver damage and disease progression
- Disease:Metabolic dysfunction-associated steatohepatitisNon-alcoholic steatohepatitis
- Substances:Resmetirom
Hungary- Participants:18–64 years · 65+ years
- Substances:Resmetirom
- Sponsor:Madrigal Pharmaceuticals Inc.















